Global Osteoporosis Drugs Market Report by Product Type (Bisphosphonates, Calcitonin, Rank Ligand Inhibitor, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Sclerostin Inhibitor, Others) Route of Administration (Oral, Injectable, Others) Countries and Company Analysis, 2024-2032

An increase in major market participants engaging in mergers and acquisitions:

Over the course of the projection period, one of the main factors propelling the market's growth will be the increasing frequency of mergers and acquisition scenarios between significant competitors in the industry.

For example, to broaden their product options and portfolio, Amge Inc., a worldwide biopharmaceutical firm with headquarters in the United States, purchased Horizon Therapeutics, a business that develops medications for rare, autoimmune, and severe inflammatory diseases, in December 2022.

Regulatory agencies approving more products:

The worldwide and Chinese osteoporosis medicine markets may rise as a result of an increase in product approvals by national regulatory agencies.

For example, on February 06, 2023, the Biologics License Application (BLA) for a proposed denosumab biosimilar was accepted by the U.S. Food and Drug Administration (FDA). A RANK ligand inhibitor called denosumab is used to treat osteoporosis in postmenopausal women who are at high risk of fracture, to increase bone mass in men who have osteoporosis and are at high risk of fracture, and to treat osteoporosis in men and women who are at high risk of fracture due to glucocorticoid-induced osteoporosis, to improve bone mass in women at high risk of fracture who are getting adjuvant aromatase inhibitor therapy for breast cancer, and in men at high risk of fracture who are receiving androgen deprivation therapy for non-metastatic prostate cancer. A worldwide healthcare organization with its headquarters located in Switzerland, Sandoz International GmbH (A subsidiary of Novartis AG) submitted the BLA (Biologics License Applications).

Growth in Healthcare Spending Powers the Osteoporosis Drug Industry:

Globally, the prevalence of diseases is increasing, and so are government and non-governmental initiatives, driving up healthcare expenses. As a result, the infrastructure supporting healthcare is improving, and access to treatment for a wide range of illnesses is becoming easier and less costly. The market is growing as a result of rising healthcare awareness, women's health maintenance, and manufacturer introductions of new products to capture a larger market share.

North America Osteoporosis Drugs Market

For the duration of the forecast period, North America is anticipated to lead the global market for osteoporosis medications. The region's high incidence of osteoporosis patients, a well-established healthcare system, the availability of branded medications, and the presence of major competitors are all contributing factors to the market's growth.

Due to the country's expanding adult population, rising patient volume, and several joint initiatives by major corporations to enhance their capacities and guarantee better medical standards, the United States holds the highest market share. For instance, the National Osteoporosis Foundation (NOF) reports that since 2020, almost 10 million Americans have received an osteoporosis diagnosis. Osteoporosis is more common in women going through menopause. As a result, it is anticipated that the rising incidence of osteoporosis in women as a result of menopause will significantly fuel growth in the local osteoporosis medication market.

The implementation of cooperative research projects by significant health organizations and corporations, as well as the creation of new products that continuously aim to enhance alternative medicines in the present market context, are additional factors contributing to the growing demand. For instance, Amgen said in 2019 that the US FDA had authorized Evenity (romosozumab-aqqg), a medication used to treat osteoporosis in postmenopausal women who are at high risk of fracture. This element can create fresh chances for the market's expansion in the area.  

Global Osteoporosis Drugs Company Analysis:

Some leading Osteoporosis Drugs companies are Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., UCB S.A.

Global Osteoporosis Drugs Company News:

Nov 2023: The United States has approved a generic version of teriparatide injectable, or Forteo, according to Teva Pharmaceuticals Inc. In certain cases, it is used to treat osteoporosis in men and women. Teva's strategic goal of remaining a dominant player in the generic market is demonstrated by this FDA clearance and the following launch, which will enhance patients' access to a significant therapeutic preference.

May 2023: Leading biotechnology company OsteoGenix announced the start of Phase III clinical trials for their cutting-edge osteoporosis medication. The medication is intended to help people with severe osteoporosis prevent fractures and protect their bones more effectively. A broader patient group will be included in the Phase III trials to evaluate the drug's safety and effectiveness.

March 2023: The U.S. Food and Drug Administration (FDA) has given regulatory approval to OsteoLife Therapeutics, a pharmaceutical firm that specializes in bone health, for its novel osteoporosis medication. In clinical trials, the medication has shown a strong correlation with increased bone strength and decreased fracture rates.

January 2023: Leading biopharmaceutical startup OsteoCure Pharmaceuticals recently reported that their innovative osteoporosis treatment candidate had successfully completed preclinical testing. Preclinical research on the medication has revealed encouraging outcomes in terms of increasing bone density and lowering the incidence of fractures.

Key Questions Answered in This Report:

Question:    How big is the Osteoporosis Drugs market?

Answer:     The global Osteoporosis Drugs market size was estimated to reach USD 25.53 billion in 2032 while it was estimated to reach US$ 17.43 billion by 2023.

Question:    What is the Osteoporosis Drugs market growth rate?

Answer:     The global Osteoporosis Drugs market is expected to grow at a compound annual growth rate of 4.33% from 2024 to 2032.

Question:    Who are the key players in Osteoporosis Drugs market?

Answer:     Some key players operating in the Osteoporosis Drugs market includes Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, etc.

Question:    What are the factors driving the Osteoporosis Drugs market?

Answer:     Key factors that are driving the Osteoporosis Drugs includes an increase in major market participants engaging in mergers and acquisitions, Regulatory agencies approving more products, etc.

Question:    Which Region held the largest market share in the Osteoporosis Drugs market?

Answer:     “North America” had the largest share in the Osteoporosis Drugs Market.

Product Type – Market Breakup in 7 Viewpoints:

1. Bisphosphonates
2. Calcitonin
3. Rank Ligand Inhibitor
4. Parathyroid Hormone Therapy (PTH)
5. Selective Estrogen Receptor Modulators (SERMs)
6. Sclerostin Inhibitor
7. Others

Route of Administration – Market Breakup in 3 Viewpoints:

1. Oral
2. Injectable
3. Others

Geography – Market Breakup of 25 Countries:

North America

1. United States
2. Canada

Europe

1. France
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Turkey

Asia Pacific

1. China
2. Japan
3. India
4. Australia
5. South Korea
6. Thailand
7. Malaysia
8. Indonesia
9. New Zealand

Latin America

1. Brazil
2. Mexico
3. Argentina

Middle East & Africa

1. South Africa
2. Saudi Arabia
3. United Arab Emirates

Company Insights:

• Overview
• Recent Development
• Product Portfolio
• Financial Insight

Key Players Analysis:

1. Amgen Inc.
2. Eli Lilly and Company
3. Hoffmann-La Roche AG
4. GlaxoSmithKline Plc
5. Merck & Co. Inc.
6. Novartis AG
7. Pfizer Inc.
8. Teva Pharmaceutical Industries Ltd.
9. UCB S.A.

Report Details: